<DOC>
	<DOCNO>NCT00871104</DOCNO>
	<brief_summary>The study evaluate efficacy safety fosfomycin imipenem treatment methicillin-resistant staphyloccocus aureus infective endocarditis comparison vancomycin , standard therapy .</brief_summary>
	<brief_title>Fosfomycin Plus Imipenem Treatment Infective Endocarditis</brief_title>
	<detailed_description />
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Endocarditis , Bacterial</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Suspected methicillinresistant staphyloccocus aureus infective endocarditis native valve , prosthetic valve pacemakers´s electrode defibrillator definitive probable diagnosis modify Duke criterion ( Li J , et al . Clin Infect Dis . 2000 ) . Patients 18 year . Patients sign inform consent . Patients active consumption intravenous drug . Patients emergent surgery criterion ( &lt; 72 hour ) . Patients cardiogenic shock . Patients antibiotic active MRSA 72 hour may need another antibiotic active MRSA study . Patients chronic renal failure hemodialysis receive empirical treatment vancomycin single dose valley ≥ 15 mcg / mL third day . Patients MRSA strain resistant fosfomycin ( MIC &gt; 64 mg / L ) ( &lt; 10 % ) vancomycin ( MIC &gt; 2 mg / L ) MIC vancomycin 2 mg / L. Patients formal contraindication treat study drug Patients treat investigational drug within 30 day prior enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Infective endocarditis</keyword>
</DOC>